REG - Oxford Biomedica PLC - Result of AGM <Origin Href="QuoteRef">OXB.L</Origin>

Oxford BioMedicaAnnouncement

23/05/2017 14:05

RNS Number : 9918F
Oxford Biomedica PLC
23 May 2017
Oxford BioMedica Annual General Meeting
London, UK - 23 May 2017: Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, announces today that all resolutions proposed were duly passed at its Annual General Meeting (AGM), held today in London.
In accordance with Listing Rule 9.6.18 the following resolutions are those which were passed at the meeting concerning special business:
 Resolution 7: to authorise the Directors to allot equity securities for cash, pursuant to section 570 of the Companies Act 2006 as if section 561 of the Companies Act 2006 did not apply to such allotment, up to an aggregate nominal amount of 5 per cent. of the presently issued shares; 
 Resolution 8: to empower the Directors to allot equity securities for cash, pursuant to section 570 of the Companies Act 2006 as if section 561 of the Companies Act 2006 did not apply to such allotment, up to an aggregate nominal amount of 5 per cent. of the presently issued shares in connection with an acquisition or specified capital investment; and
 Resolution 9: to permit the Directors to convene general meetings (other than annual general meetings) on not less than 14 days' notice. 
The full text of all the resolutions can be viewed in the Notice of Meeting by visiting the Group's website at www.oxfordbiomedica.co.uk.
Certified copies of the document setting out the above resolutions passed at the 2017 AGM have been submitted to the National Storage Mechanism and will shortly be available for inspection at: http://www.morningstar.co.uk/uk/NSM.
The results of the proxy voting in advance of the meeting are shown below. On the Record Date (19 May 2017) there were 3,088,326,065 1p ordinary shares in issue, each carrying one vote per share.
Resolution
Votes
For
Votes at
Chairman's
Discretion
Votes at
other proxy
Discretion
Votes
Against
Votes
Withheld
Total
votes cast
Result








Ordinary resolutions













1
1,888,465,188
802,799
6,958,793
604,970
398,641
1,897,230,391
Passed








2
1,601,919,465
928,694
6,958,793
4,701,911
282,721,528
1,897,230,391
Passed








3
1,880,264,095
868,254
6,958,793
1,126,450
8,012,799
1,897,230,391
Passed
4
1,880,712,558
872,425
6,958,793
664,300
8,022,315
1,897,230,391
Passed








5
1,813,674,842
880,635
6,958,793
75,322,036
394,085
1,897,230,391
Passed








6
1,887,924,882
925,661
6,958,793
857,070
563,985
1,897,230,391
Passed
Special resolutions






7
1,774,042,262
1,002,090
6,958,793
1,619,809
113,607,437
1,897,230,391
Passed








8
1,887,104,129
1,002,090
6,958,793
1,557,942
607,437
1,897,230,391
Passed
























9
1,879,803,796
1,001,125
6,958,793
9,042,530
424,147
1,897,230,391
Passed
















- Ends -
For further information, please contact:
Oxford BioMedica plc:
John Dawson, Chief Executive Officer
Tim Watts, Chief Financial Officer
Tel: +44 (0)1865 783 000
Consilium Strategic Communications
Mary-Jane Elliott/Matthew Neal/Chris Welsh/Laura Thornton
Tel: +44 (0)20 3709 5700
Notes for editors
About Oxford BioMedica
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy company focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector) through which the Group developsin vivoandex vivoproducts both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, GSK, and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 250 people. Further information is available atwww.oxfordbiomedica.co.uk.

This information is provided by RNS
The company news service from the London Stock Exchange
  END
RAGSEFFDDFWSESI